Hepatocellular Carcinoma

Tivantinib Fails to Improve Overall Survival As Second-Line Treatment in Liver Cancer

Tivantinib Fails to Improve Overall Survival As Second-Line Treatment in Liver Cancer

By

Previous studies have demonstrated tivantinib prolonged progression-free survival and overall survival in hepatocellular carcinoma.

Radioembolization Shows Similar OS, Improved Toxicity vs Sorafenib in Hepatocellular Carcinoma

Radioembolization Shows Similar OS, Improved Toxicity vs Sorafenib in Hepatocellular Carcinoma

By

Patients were enrolled regardless of portal vein thrombosis status and were unable to tolerate other curative therapies.

Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma

Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma

By

Researchers evaluated whether the PD-1 inhibitor would improve outcomes among patients with HCC who progressed after sorafenib treatment.

Cabozantinib May Improve Survival Outcomes in Relapsed Hepatocellular Carcinoma

Cabozantinib May Improve Survival Outcomes in Relapsed Hepatocellular Carcinoma

By

Researchers randomly assigned 707 patients with advanced HCC to receive oral cabozantinib 60 mg once daily or placebo.

SIRT Does Not Improve Overall Survival vs Sorafenib in Hepatocellular Carcinoma

SIRT Does Not Improve Overall Survival vs Sorafenib in Hepatocellular Carcinoma

By

Researchers randomly assigned 459 patients to receive SIRT with 90Y-loaded resin microspheres for 2 to 5 weeks or oral sorafenib 400 mg twice daily continuously.

Oranitib Plus cTACE Fails to Prolong Overall Survival in Hepatocellular Carcinoma

Oranitib Plus cTACE Fails to Prolong Overall Survival in Hepatocellular Carcinoma

By

A previous study demonstrated that TACE plus orantinib insignificantly prolonged progression-free survival, though it did not improve OS.

Lenvatinib May Delay Functional Deterioration in Hepatocellular Carcinoma

Lenvatinib May Delay Functional Deterioration in Hepatocellular Carcinoma

By

Patients had similar HRQOL scores by all measures at baseline, but experienced significant changes in scores for the HRQOL domains of Body Image, Diarrhea, Nutrition, Pain, and Role Function.

Patients With Hepatocellular Carcinoma May Benefit From TACE Plus Axitinib

Patients With Hepatocellular Carcinoma May Benefit From TACE Plus Axitinib

By

The combination of axitinib and TACE is safe and potentially efficacious for patients with inoperable hepatocellular carcinoma.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs